CN114929240B - 脱氧胞苷的多晶型形式、包含其的组合物和用途 - Google Patents
脱氧胞苷的多晶型形式、包含其的组合物和用途 Download PDFInfo
- Publication number
- CN114929240B CN114929240B CN202080073216.4A CN202080073216A CN114929240B CN 114929240 B CN114929240 B CN 114929240B CN 202080073216 A CN202080073216 A CN 202080073216A CN 114929240 B CN114929240 B CN 114929240B
- Authority
- CN
- China
- Prior art keywords
- ppm
- deoxycytidine
- mixture
- composition
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888893P | 2019-08-19 | 2019-08-19 | |
| US62/888893 | 2019-08-19 | ||
| PCT/US2020/047047 WO2021034962A1 (en) | 2019-08-19 | 2020-08-19 | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114929240A CN114929240A (zh) | 2022-08-19 |
| CN114929240B true CN114929240B (zh) | 2024-10-29 |
Family
ID=74647126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080073216.4A Active CN114929240B (zh) | 2019-08-19 | 2020-08-19 | 脱氧胞苷的多晶型形式、包含其的组合物和用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11649259B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017502A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7769603B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929240B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020334060B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022002513A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150755A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034962A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022204555A1 (en) * | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| WO2026082601A2 (en) * | 2024-10-15 | 2026-04-23 | UCB Biopharma SRL | Method of purification |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002293791A (ja) * | 2001-03-30 | 2002-10-09 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の精製法 |
| CN107847512A (zh) * | 2015-06-17 | 2018-03-27 | 纽约市哥伦比亚大学理事会 | 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898936A (en) * | 1984-09-24 | 1990-02-06 | Pcr, Inc. | 2-deoxyuridines and riboside precursors |
| JPS61135597A (ja) * | 1984-12-06 | 1986-06-23 | Takeda Chem Ind Ltd | シチジンおよびデオキシシチジンの製造法 |
| US4900828A (en) * | 1988-05-12 | 1990-02-13 | Hoffmann-Laroche Inc. | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine |
| JP2002255991A (ja) * | 2000-12-27 | 2002-09-11 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の製造法 |
| CN100424091C (zh) * | 2002-06-05 | 2008-10-08 | 三井化学株式会社 | 保护化2’-脱氧胞苷类的精制法 |
| EP1551838B1 (en) * | 2002-10-16 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US9669048B2 (en) * | 2012-10-25 | 2017-06-06 | Fresenius Kabi Oncology Limited | Stable pharmaceutical composition of 5-aza-2′-deoxycitidine |
| GB2580963C (en) * | 2019-02-01 | 2025-09-03 | Hemispherian As | Cancer therapies |
-
2020
- 2020-08-19 EP EP20854948.5A patent/EP4017502A4/en active Pending
- 2020-08-19 AU AU2020334060A patent/AU2020334060B2/en active Active
- 2020-08-19 BR BR112022002513A patent/BR112022002513A2/pt unknown
- 2020-08-19 US US16/997,727 patent/US11649259B2/en active Active
- 2020-08-19 JP JP2022510955A patent/JP7769603B2/ja active Active
- 2020-08-19 CN CN202080073216.4A patent/CN114929240B/zh active Active
- 2020-08-19 CA CA3150755A patent/CA3150755A1/en active Pending
- 2020-08-19 WO PCT/US2020/047047 patent/WO2021034962A1/en not_active Ceased
-
2025
- 2025-07-10 JP JP2025116467A patent/JP2025160233A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002293791A (ja) * | 2001-03-30 | 2002-10-09 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の精製法 |
| CN107847512A (zh) * | 2015-06-17 | 2018-03-27 | 纽约市哥伦比亚大学理事会 | 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法 |
Non-Patent Citations (1)
| Title |
|---|
| M.D. Bratek-Wiewiorowska et al.."Multiforms and behavior of crystalline 2'-deoxycytidine".Journal of Molecular Structure.1998,(第448期),摘要、第177页右栏第1-3段以及图1. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7769603B2 (ja) | 2025-11-13 |
| AU2020334060A1 (en) | 2022-03-24 |
| US20210054014A1 (en) | 2021-02-25 |
| EP4017502A4 (en) | 2023-11-01 |
| CN114929240A (zh) | 2022-08-19 |
| JP2025160233A (ja) | 2025-10-22 |
| EP4017502A1 (en) | 2022-06-29 |
| CA3150755A1 (en) | 2021-02-25 |
| AU2020334060B2 (en) | 2024-11-14 |
| JP2022544831A (ja) | 2022-10-21 |
| US11649259B2 (en) | 2023-05-16 |
| BR112022002513A2 (pt) | 2022-05-03 |
| WO2021034962A1 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110636884B (zh) | 新结晶形式 | |
| JP2025160233A (ja) | デオキシシチジンの多形形態、それを含む組成物および使用 | |
| TWI920053B (zh) | 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌-1-基]戊-2-烯腈之晶形 | |
| TW201136593A (en) | Nucleoside phosphoramidates | |
| US20230151048A1 (en) | Crystal form, preparation method, and application of 4′-substituted nucleoside | |
| ES2959891T3 (es) | Producción de trans-[tetraclorobis(1H-indazol)rutenato (III)] y composiciones del mismo | |
| JP7235661B2 (ja) | 3-ヒドロキシ-4,5-ビス-ベンジルオキシ-6-ベンジルオキシメチル-2-フェニル-2-オキソ-2λ5-[1,2]オキサホスフィナンの結晶多形体 | |
| BR112019014825A2 (pt) | Composição farmacêutica compreendendo um derivado de oxazina e seu uso no tratamento ou prevenção da doença de alzheimer | |
| CN102770416B (zh) | 美他沙酮共晶体 | |
| US20260091039A1 (en) | Hydrochloric acid salt of a 5-ht2c agonist | |
| CA3148866A1 (en) | Dinucleotide compounds for treating cancers and medical uses thereof | |
| CN108218936B (zh) | 联苯核苷氨基磷酸酯化合物的异构体及其无定型物 | |
| CN105308043B (zh) | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 | |
| WO2023105483A1 (en) | Crystalline forms of a 5-aminopyrazole compound useful for treating hbv | |
| KR20210155806A (ko) | Pi3k 저해제의 결정다형 및 이의 제조방법 | |
| CN116829153A (zh) | 治疗流感化合物的晶型及应用 | |
| JP6298532B2 (ja) | Hcvのヌクレオシド阻害剤の結晶形 | |
| JPS60224622A (ja) | 強心剤 | |
| CN112010905A (zh) | 甲磺酸帕拉德福韦晶型及其应用 | |
| CN104844592A (zh) | 盐酸托烷司琼晶iii型物质及制备方法和其组合物与用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: California, USA Applicant after: Zhougenix Modis Co. Address before: California, USA Applicant before: MODIS treatment Co. Country or region before: U.S.A. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240411 Address after: California, USA Applicant after: Zhouge Knicks Co. Country or region after: U.S.A. Address before: California, USA Applicant before: Zhougenix Modis Co. Country or region before: U.S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20241112 Address after: North Carolina, USA Patentee after: Ushibi Bioscience Co. Country or region after: U.S.A. Address before: California, USA Patentee before: Zhouge Knicks Co. Country or region before: U.S.A. |